Several measures of haemostasis and fibrinolysis were tested in 34 patients with cerebral haemorrhage and 47 patients with cerebral infarction within 11 days of the event. No significant differences were found between the two groups, but in comparison with a control group the following values were significantly elevated as the result of coagulation and fibrinolysis: fibrin monomers, thrombin-antithrombin-III, D-dimers and tissue plasminogen activator activity. In approximately 11 % of the patients the fibrin monomer levels were elevated to such an extent (> 30 mmol/1) that they were compatible with activation of the coagulation system. It is not possible to differentiate between cerebral infarction and cerebral haemorrhage by means of coagulation or fibrinolysis parameters. In the fibrin-monomer-negative group 22 % of the patients died, compared with 56% in the fibrin-monomer-positive group. Thus a state of hypercoagulability may have a negative effect on prognosis. Follow-up of 4 patients with cerebral haemorrhage showed that the abnormalities of coagulation and fibrinolysis parameters could last as long as 4 weeks.

Keywords:
Coagulation, Fibrinolysis, Stroke
This content is only available via PDF.
© 1992 S. Karger AG, Basel
1992
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.